Smallpox - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 90 pages report, published by Global Markets Direct

Keywords : Smallpox Therapeutic Products under Development, Key Players in Smallpox Therapeutics, Smallpox Pipeline Overview, Smallpox Pipeline, Smallpox Pipeline Assessment

Report ThumbnailSeptember-2013
Smallpox - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Smallpox - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Smallpox, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Smallpox. Smallpox - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Smallpox.
- A review of the Smallpox products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Smallpox pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Smallpox.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Smallpox pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Smallpox, H2 2013 9
  • Products under Development for Smallpox - Comparative Analysis, H2 2013 10
  • Products under Development by Companies, H2 2013 11
  • Late Stage Products, H2 2013 13
  • Mid Clinical Stage Products, H2 2013 14
  • Early Clinical Stage Products, H2 2013 15
  • Discovery and Pre-Clinical Stage Products, H2 2013 16
  • Assessment by Monotherapy Products, H2 2013 31
  • Assessment by Route of Administration, H2 2013 32
  • Assessment by Stage and Route of Administration, H2 2013 33
  • Assessment by Molecule Type, H2 2013 34
  • Assessment by Stage and Molecule Type, H2 2013 35
  • List of Tables
  • Number of Products Under Development for Smallpox, H2 2013 9
  • Products under Development for Smallpox - Comparative Analysis, H2 2013 10
  • Number of Products under Development by Companies, H2 2013 12
  • Comparative Analysis by Late Stage Development, H2 2013 13
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013 14
  • Comparative Analysis by Early Clinical Stage Development, H2 2013 15
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 16
  • Products under Development by Companies, H2 2013 17
  • Inovio Biomedical Corporation, H2 2013 18
  • Bavarian Nordic A/S, H2 2013 19
  • Symphogen A/S, H2 2013 20
  • Nanotherapeutics, Inc., H2 2013 21
  • CEL-SCI Corporation, H2 2013 22
  • GeoVax Labs, Inc., H2 2013 23
  • SIGA Technologies, Inc., H2 2013 24
  • TapImmune Inc., H2 2013 25
  • MacroGenics, Inc., H2 2013 26
  • AlphaVax, Inc., H2 2013 27
  • EpiVax, Inc., H2 2013 28
  • Chimerix, Inc., H2 2013 29
  • NanoBio Corporation, H2 2013 30
  • Assessment by Monotherapy Products, H2 2013 31
  • Assessment by Stage and Route of Administration, H2 2013 33
  • Assessment by Stage and Molecule Type, H2 2013 35
  • Smallpox Therapeutics - Drug Profile Updates 66
  • Smallpox Therapeutics - Dormant Products 81
  • Table of Contents
  • Table of Contents 2
  • List of Tables 5
  • List of Figures 6
  • Introduction 7
  • Global Markets Direct Report Coverage 7
  • Smallpox Overview 8
  • Therapeutics Development 9
  • An Overview of Pipeline Products for Smallpox 9
  • Smallpox Therapeutics under Development by Companies 11
  • Late Stage Products 13
  • Comparative Analysis 13
  • Mid Clinical Stage Products 14
  • Comparative Analysis 14
  • Early Clinical Stage Products 15
  • Comparative Analysis 15
  • Discovery and Pre-Clinical Stage Products 16
  • Comparative Analysis 16
  • Smallpox Therapeutics - Products under Development by Companies 17
  • Companies Involved in Smallpox Therapeutics Development 18
  • Inovio Biomedical Corporation 18
  • Bavarian Nordic A/S 19
  • Symphogen A/S 20
  • Nanotherapeutics, Inc. 21
  • CEL-SCI Corporation 22
  • GeoVax Labs, Inc. 23
  • SIGA Technologies, Inc. 24
  • TapImmune Inc. 25
  • MacroGenics, Inc. 26
  • AlphaVax, Inc. 27
  • EpiVax, Inc. 28
  • Chimerix, Inc. 29
  • NanoBio Corporation 30
  • Smallpox - Therapeutics Assessment 31
  • Assessment by Monotherapy Products 31
  • Assessment by Route of Administration 32
  • Assessment by Molecule Type 34
  • Drug Profiles 36
  • brincidofovir - Drug Profile 36
  • Product Description 36
  • Mechanism of Action 36
  • R&D Progress 36
  • Sym-002 - Drug Profile 38
  • Product Description 38
  • Mechanism of Action 38
  • R&D Progress 38
  • cidofovir - Drug Profile 39
  • Product Description 39
  • Mechanism of Action 39
  • R&D Progress 39
  • live modified vaccinia virus ankara - Drug Profile 40
  • Product Description 40
  • Mechanism of Action 40
  • R&D Progress 40
  • live modified vaccinia virus ankara - Drug Profile 42
  • Product Description 42
  • Mechanism of Action 42
  • R&D Progress 42
  • CEL-1000 - Drug Profile 44
  • Product Description 44
  • Mechanism of Action 44
  • R&D Progress 44
  • tecovirimat - Drug Profile 46
  • Product Description 46
  • Mechanism of Action 46
  • R&D Progress 46
  • tecovirimat - Drug Profile 48
  • Product Description 48
  • Mechanism of Action 48
  • R&D Progress 48
  • tecovirimat - Drug Profile 50
  • Product Description 50
  • Mechanism of Action 50
  • R&D Progress 50
  • DNA Vaccine For Smallpox - Drug Profile 52
  • Product Description 52
  • Mechanism of Action 52
  • R&D Progress 52
  • Smallpox Vaccine - Drug Profile 53
  • Product Description 53
  • Mechanism of Action 53
  • R&D Progress 53
  • CST-102 - Drug Profile 54
  • Product Description 54
  • Mechanism of Action 54
  • R&D Progress 54
  • Smallpox Vaccine - Drug Profile 55
  • Product Description 55
  • Mechanism of Action 55
  • R&D Progress 55
  • CJ-50300 - Drug Profile 56
  • Product Description 56
  • Mechanism of Action 56
  • R&D Progress 56
  • Modified Vaccinia Ankara Transporters Associated with Antigen Processing - Drug Profile 57
  • Product Description 57
  • Mechanism of Action 57
  • R&D Progress 57
  • Elstree-BN Smallpox Vaccine - Drug Profile 59
  • Product Description 59
  • Mechanism of Action 59
  • R&D Progress 59
  • Mult. mAbs/DARTs - Drug Profile 60
  • Product Description 60
  • Mechanism of Action 60
  • R&D Progress 60
  • MVA Vaccine - Drug Profile 61
  • Product Description 61
  • Mechanism of Action 61
  • R&D Progress 61
  • SmallPox Vaccine - Drug Profile 63
  • Product Description 63
  • Mechanism of Action 63
  • R&D Progress 63
  • PL-801 - Drug Profile 64
  • Product Description 64
  • Mechanism of Action 64
  • R&D Progress 64
  • IkT-001 Pro - Drug Profile 65
  • Product Description 65
  • Mechanism of Action 65
  • R&D Progress 65
  • Smallpox Therapeutics - Drug Profile Updates 66
  • Smallpox Therapeutics - Dormant Products 81
  • Smallpox - Product Development Milestones 82
  • Featured News & Press Releases 82
  • Aug 07, 2013: Bavarian Nordic Receives European Marketing Authorization for IMVANEX Smallpox Vaccine 82
  • Jun 03, 2013: Chimerix And BARDA Continue Collaboration On Development Of CMX001 As Medical Countermeasure Against Smallpox 83
  • May 31, 2013: Bavarian Nordic's Imvanex Vaccine Receives Positive CHMP Opinion For Active Immunization Against Smallpox 84
  • May 29, 2013: SIGA Completes Second Delivery Of Arestvyr Under BARDA Contract 84
  • May 26, 2013: PharmAthene Announces Delaware Supreme Court Upholds Lower Court Ruling In Lawsuit Against SIGA Technologies 85
  • May 16, 2013: Chimerix Presents Data On CMX001 At 26th International Conference On Antiviral Research 85
  • Apr 16, 2013: Bavarian Nordic Receives Contract Valued Up To $228m From BARDA Securing Continued Production And Deliveries Of Imvamune Smallpox Vaccine 86
  • Mar 12, 2013: Siga Delivers First Courses Of Arestvyr To US Strategic National Stockpile Under BARDA Contract 87
  • Jan 10, 2013: PharmAthene Announces Delaware Supreme Court Hears Oral Arguments In Litigation With Siga Technologies 88
  • Nov 29, 2012: Siga Technologies Announces New Brand Name For Small Pox Drug ST-246 88
  • Appendix 89
  • Methodology 89
  • Coverage 89
  • Secondary Research 89
  • Primary Research 89
  • Expert Panel Validation 89
  • Contact Us 90
  • Disclaimer 90

Please select a license type

Share

Related Products

Global Markets DirectSmallpox - Pipeline Review, H2 2013Product ThumbnailSmallpox - Pipeline Review, H2 2013, Industry ReportProduct #: 113287
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved